Wednesday, 30 January 2019

Agnosia Treatment Market 2018–By Identifying the Key Market Segments and Key players holding market share

Market Scenario
Agnosia is a rare neurological condition in which an individual may face difficulty to process sensory information like recognizing a familiar person, sound or object. It is due to occurrence of lesions in the brain. Medical conditions such as dementia, stroke, head injury or any other neurological condition may lead to development of agnosia. Moreover, there are several conditions that may cause brain lesions and are associated with agnosia.
People suffering from agnosia can still interact with others normally. As such agnosia affects a single pathway when brain suffers a certain damage. The pathway might connect primary sensory areas that store information and knowledge. The primary sensory regions mainly include visual or auditory cortices. According to the World Health Organization (WHO) estimates, neurological disorders are responsible for 4.5%-11% of all illnesses including low or high income economies.
Brain imaging techniques such as CT or MRI with or without angiographic protocols is required to characterize a central lesion such as hemorrhage, infarct or mass and also might check medical history of the patient and atrophy suggesting a degenerative disorder.
Many individuals suffering from agnosia can still retain their cognitive abilities, such as reading and basic math. The condition affects everyone differently but it can significantly impact the quality of life.
The cause of this disorders may precede the development of primary visual agnosia. Some causes of agnosia include diseases such as Alzheimer’s, Pick’s disease, Balint’s syndrome.  Alzheimer’s is a common, progressive, degenerative brain disorder affecting memory, thought, and language. Pick’s disease is also a degenerative neurological disorder that closely resemble the symptoms of Alzheimer’s disease. Balint’s syndrome is a rare neurological disorder characterized by the inability to voluntarily look at objects to the side. Individuals often cannot read, grasp or view one’s surroundings as a whole (simultanagnosia).
Some of the most probable causes of this disease are dementia, carbon monoxide poisoning, encephalitis, traumatic brain injuries and strokes. Physical examination is performed to detect any primary deficits in individual related to senses or inability to infer any test for agnosia.  According to WHO, the total number of people with dementia worldwide is projected to nearly double every 20 years, to 65.7 million in 2030 and 115.4 million in 2050. The total number of new cases of dementia each year is nearly 7.7 million worldwide, implying one new case every four seconds.
There is no specific treatment for agnosia. If doctors are able to identify the cause, the treatment will be tailored to the specific problem. For example, if an abscess is causing agnosia, the doctor may prescribe antibiotics and refer for a surgery to drain the abscess. Rehabilitation with speech or occupational therapists can help patients learn to compensate for their deficits.
Organizations such as the National Institute of Neurological Disorders and Stroke (NINDS) collects and disseminates research information related to neurological disorders. Furthermore, the National Organization for Rare Disorders (NORD) has a report for patients and families about this condition. NORD is a patient advocacy organization for individuals with rare diseases and the organizations that serve them.
The global market of agnosia treatment is expected to grow at a CAGR of approximately 7.2% during the forecast period 2017-2023.
Key Players
Some of key the players in the global agnosia treatment market are B. Braun Melsungen (Germany), Pfizer Inc. (U.S.),  Lupin ltd. (India), Fujifilm Holdings (Japan), GE Healthcare (U.S.), Siemens Healthcare(U.S.), Philips Healthcare (U.S.), F. Hoffmann-La Roche AG (Switzerland) , Aurobindo Pharma Ltd (India), Sandoz GmBH (Austria), Stellar- Bio Labs (India), Fresenius Kabi Ipsum SRL (Italy), Zhuhai United Laboratories Co Ltd (China), Cspc Zhongnuo Pharmaceutical Shijiazhuang Co Ltd (China), IPCA Labs ltd. (India) and others.
Segmentation
The agnosia treatment market is segmented on the basis of is segmented on the basis of diagnosis, causes, type, and treatment.
On the basis of diagnosis it is segmented into Computed Tomography (CT), Magnetic Resonance Imaging (MRI), and others.
On the basis of causes it is segmented into Alzheimer's disease, Pick's disease, MELAS, Balint's syndrome.
On the basis of the type, it is segmented into auditory agnosia, gustatory agnosia, olfactory agnosia, tactile agnosia, visual agnosia, and others. Others is further segmented into prosopagnosia and anosognosia
On the basis of treatment, it is segmented into surgery, antibiotics for cerebral absess and radiation of brain tumor. Antibiotics for cerebral absess is further segmented into Ceftriaxone and Cefotaxime+metronidazole
Regional Analysis
The global agnosia treatment market consists of countries namely America, Europe, Asia Pacific, and the Middle East & Africa.
North America dominated the global agnosia treatment market owing to the increasing healthcare expenditure. The increasing incidence of accidents and brain injury is leading to development of new treatment methods are some of the driving factors responsible for the growth of the global agnosia treatment market.
Europe holds the second position in the global agnosia treatment owing to the government support for research & development and availability of funds for research. People with agnosia can benefit from speech and occupational therapy provided by the various European medical organisations such as Alzheimer Europe, and the European Conference on Visual Perception (ECVP) to learn how to deal with this impairment in their daily life.
Asia Pacific is the fastest growing agnosia treatment owing to the presence of rapidly developing healthcare technology, increasing stressful life, and high healthcare expenditure. Furthermore in the Middle East & Africa the spending for healthcare was also increased. The Middle East & Africa holds the least share of the market owing to less availability of funds, limited medical facilities, and deprived political conditions in Africa.
Browse Complete 85 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/agnosia-treatment-market-5045  

  
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:

Anoxia Market Growth and Restrain Factors Analysis By 2023

Market Scenario
Anoxia is a condition that occurs due to complete loss of oxygen in body or brain which leads to various cognitive problems, and disabilities. It is considered as a severe cause of hypoxia. The most common causes of anoxia are respiratory arrest, drowning, carbon monoxide inhalation, illegal drug use, brain tumors, heart arrhythmia, suffocation, compression of the trachea, heart attack, and many others. Anoxic brain injury is also known as hypoxic-anoxic injury (HAI) or cerebral hypoxia. There are different types of anoxia, and each has an internal, and external causes. For instance, anemic anoxia occurs when blood is unable to carry enough oxygen to keep organs functioning properly, whereas, stagnant anoxia occurs when blood doesn’t reach brain or other body parts properly. Cardiovascular events such as, heart attack, cardiac arrhythmia, heart failure, and stroke, are the most common causes of stagnant anoxia. Anoxic anoxia usually at high altitudes. According to a study published in the Neural Regeneration Research journal, it is found that the with the increasing altitude partial pressure of oxygen falls which results in anoxic challenge to the person ascending to high altitudes.
Short-term memory loss, poor performance in executive functions, anomia, and visual disturbances are the commonly known cognitive problems associated with anoxia, whereas, physical problems include ataxia (lack of coordination), apraxia (inability to do common tasks), movement disorders, quadriparesis, and headaches.
Notably, rising cases of cardiac arrest is the key factor driving the anoxia market. According to a study published in the Critical Care journal in 2017, it is found that hypoxic ischemic brain injury (HIBI) is an outcome of cardiac arrest. It is stated that HIBI is the major cause of death in 23% of out-of-hospital cardiac arrest, and in 68% of inpatient cardiac arrest.
Various other factors such as, increasing awareness among people, increasing government assistance, and improvement in regulatory framework continuously contribute to the growth of the global anoxia market.
Despite these drivers, there are some issues associated with anoxia market. Challenges in research and development, and poor healthcare system in low and middle income countries may hinder the growth of market to an extent.
It is estimated that anoxia market is expected to grow at a CAGR 5.4% during the forecast period of 2017-2023.
Segmentation
The anoxia market is segmented on the basis of type, diagnosis, treatment, and end-user.
On the basis of type, market is segmented into anemic anoxia, toxic anoxia, stagnant anoxia, and anoxic anoxia.
On the basis of diagnosis, market is classified into blood tests, MRI (magnetic resonance imaging), CT or CAT scan (computerized axial tomography), evoked potential tests, and EEG (electroencephalogram).
On the basis of treatment, market is classified into cardiopulmonary resuscitation (CPR), rehabilitation therapies, and medication. Rehabilitation therapies is further segmented into speech therapy physical therapy, occupational therapy, recreational therapy, and adaptive equipment training. Medication is also further classified into ammonia reducer, anticonvulsant, steroids, vitamin, and others.
On the basis of end-users, market is segmented into hospital & clinics, diagnostic centers, research institutes, rehabilitation Centers, and others.
Regional Analysis
The Americas dominate the anoxia market owing to the rise in awareness among people, and high healthcare expenditure. According to the Centers for Disease Control and Prevention, in 2015, the total health expenditure in the United States was reported to be USD 3.2 trillion and hospital care accounted for a share of 32.3%.
Europe holds the second position in anoxia market. It is expected that the support provided by government bodies for research & development and improvement in reimbursement policies in healthcare will drive the market in Europe region.
Asia Pacific is the fastest growing anoxia market owing to the huge patient pool and developing healthcare technology. Healthcare expenditure is also improving in various Asia Pacific countries. According to the Australian Institute of Health and Welfare, in the years 2015 to 2016, the total health expenditure was USD 170.4 billion, which is 3.6% higher than expenditure of 2014–15.
The Middle East & Africa has the lowest market for anoxia due to lack of technical knowledge and poor medical facilities.
Key Players
Some of key the players in the anoxia market are Pfizer, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc,, Cephalon Inc., Shire, UCB S.A, and others.
Browse Complete 85 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/anoxia-market-4989

        
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:

Palliative Care Market 2018 Share, Trend, Segmentation and Forecast to 2023

Market Scenario 
Increasing incidence of diseases such as cancer, cardiovascular and infective disease are some of the drivers responsible for the market growth of global palliative care market. Other factors such as a growing number of palliative care centers worldwide, expanding aging demographics, increasing number of qualified physicians for palliative care are responsible for the rise in the global palliative market. The main object of palliative care is to enhance personal satisfaction for both the patient and family. This palliative care can be provided at any age and at any phase in a genuine ailment and can be furnished alongside remedial treatment.
But the high cost of treatment, less private or public funding to hospital facilities and other medical centers can be a major restraint for the growth of the global palliative care market.
Global Palliative Care market is expected to grow during the forecast period (2018–2023) at a CAGR ~8.1 %.
Palliative care helps to improve the quality of life of patients and their families facing the problems of serious illness. The main focus of Palliative care is to provide relief from symptoms and stress of a serious illness. Their main goal is to improve the quality of life for both the patient and the family. Palliative care treats people living with a serious illness such as cancer, cardiac diseases such as congestive heath failure, kidney failure, Alzheimer’s and many more. It improves the quality of life of the patient and supports the primary physician, patient, and family. In last 15 years, the Palliative care market has a stunning growth and the factors that have led to the growth of this market are growing the aging population, increase in chronic life-threatening disease, initiative taken by the government and non- profit organization, and rise in government funding.  
However, the high cost of treatment, misuse of funding and lack of awareness are some of the factors which are hampering the growth of the market during the forecast period.
Key Players
  • Vitas Healthcare Corporation
  • Skilled Healthcare Group Incorporated
  • Sunrise Senior Living LLC
  • Kindred Healthcare Incorporated
  • Gentiva Health Services Incorporated
  • Home Instead Senior Care Incorporated
  • Amedisys Incorporated
  • Genesis HealthCare Corporation
Segmentation
The Global Palliative Care Market is segmented into types such as private residence care, hospice inpatient care, hospital inpatient care, nursing home and residential facility care and others. On the basis of application, the market is further segmented into cancer, cardiac diseases such as congestive heart failure (CHF), chronic obstructive pulmonary disease (COPD), kidney failure, Alzheimer’s, Parkinson’s, Amyotrophic Lateral Sclerosis (ALS) and many more. On basis of end-user, the market is further segmented into hospitals, home care settings, palliative care centers, long-term care centers & rehabilitation centers.
Regional Market Summary
In terms of market value, North America will dominate the Palliative care market during the forecast period. Increasing incidences of life-threatening illness such as cancer, cardiovascular diseases, Alzheimer’s disease, kidney failure, chronic obstructive pulmonary disease and many more are some of the factors which are responsible for the growth of the market during the forecast period. In 2015 on average 90 % of US hospitals containing 300 beds or more provide Palliative care services to their patients. This has led to the growth of the market in coming years. The European market is expected to be the second-largest Palliative care market. The market growth in this region can be attributed to government funding and support of the healthcare sector coupled with increasing research and development. Moreover, a growing number of Palliative care centers worldwide, extending application for homecare, increasing number of qualified physicians for Palliative care center and expanding aging demographics are some of the factors responsible for the rise in the global Palliative care market. Asia-Pacific is expected to be the fastest-growing Palliative care market during the forecast period owing to the increasing prevalence of cardiac diseases, rising investments in healthcare, increasing geriatric population, and expansions by market players in the region. Asia-Pacific is giving the strong competition in the global Palliative care market by producing a cost-effective treatment that is high in demand in local as well as in the global market. The market in the Middle East and Africa is expected to account for the smallest share in the global Palliative care market due to the underdeveloped healthcare sector, lack of technical knowledge, and poor medical facilities.
The market has been segmented, by region, into the Americas, Europe, Asia Pacific, and the Middle East and Africa. The Global Palliative Care Market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada. The European Global Palliative Care Market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The Global Palliative Care Market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The Palliative care market in the Middle East and Africa has been segmented into the Middle East and Africa.

About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:

Tuesday, 29 January 2019

Rectovaginal Fistula Market in depth study and analysis published, 2018

Market Scenario
Global rectovaginal fistula market is expected to grow significantly over the forecast period. The market held a market value of USD 950 million in 2017 and is projected to grow at a CAGR of 5.4% over the forecast period. Rectovaginal fistula is abnormal connection between lower portion of large intestine- rectum-vagina. There are various causes of rectovaginal fistula such as Crohn's disease, cancer or radiation treatment in pelvic area, surgery involving vagina, perineum, rectum or anus, injuries during childbirth, and others.
The factors such as increasing prevalence pelvic cancer, Crohn’s disease is the major driving factors for the market. Moreover, increasing adoption of personalized medicine, as personalised medicine has many applications in cancer treatment. Furthermore, growing diagnosis methods for rectovaginal fistula will boost the market growth during forecast period.
However, high cost of the surgery may hamper the growth of the market during the forecast period.
According to National Cancer Institute, in 2018, an estimated 1,735,350 new cases of cancer were diagnosed in the United States and 609,640 people may die from the disease.
 Segmentation
The global rectovaginal fistula market has been segmented into diagnosis, treatment, and end user.
By diagnosis, the market has been segmented into physical exam, contrast tests, blue dye test, computerized tomography (CT) scan, magnetic resonance imaging (MRI), anorectal ultrasound, anorectal manometry, and others.
Based on treatment, the market has been segmented into medications and surgery. Medications is further segmented into antibiotics and infliximab. Surgery is further segmented into sewing an anal fistula plug or patch of biologic tissue into the fistula, using a tissue graft, repairing the anal sphincter muscles, performing a colostomy before repairing a fistula in complex or recurrent cases.
The rectovaginal fistula market, by end user, has been segmented into hospitals & clinics, diagnostic centres, academic institutions and research organizations, and others.
The global rectovaginal fistula market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The rectovaginal fistula market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.         
The European rectovaginal fistula market has been segmented into Western Europe and Eastern Europe. The Western Europe rectovaginal fistula market has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.      
The rectovaginal fistula market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The rectovaginal fistula market in the Middle East & Africa has been segmented into the Middle East and Africa.       
Key players
Cook Medical, Takeda Pharmaceutical Company, Johnson & Johnson Services Inc., Pfizer Inc., Allergan, AbbVie Inc, Novartis International AG, Bayer AG, Bristol-Myers Squibb, Boehringer Ingelheim GmbH, F. Hoffmann-La Roche, Eli Lilly and Company, GlaxoSmithKline plc, Sanofi S.A are some of the prominent players in the global rectovaginal fistula market.
Regional Market Summary
Geographically, the Americas is anticipated to dominate the global rectovaginal fistula market owing to the high domestic income, and presence of major market players. Moreover, increasing patient population in US. According to American Cancer Society, the overall estimate of 1,735,350 cases for 2018 equals more than 4,700 new cancer diagnoses each day.
Europe is expected to hold the second largest position in the global rectovaginal fistula market. The market growth in this region is attributed to the presence of strong academic & research base and availability of funding for research in the European countries. For instance, the European Research Council (ERC) provides grants for technological and scientific research conducted within the European Union (EU). 
The rectovaginal fistula market in Asia-Pacific region consists of countries namely China, Japan, Republic of Korea, India, Australia and Rest of Asia-Pacific. The Asia-Pacific region is expected to be fastest growing region owing to increasing government focus on biotechnology and pharmaceutical sector and growing number of target population in the region.   
The Middle East & Africa has the lowest share of the global rectovaginal fistula market. Majority of the market of the region is anticipated to be held by the Middle East region owing to the growing government initiatives for the healthcare sector. 
Browse Complete 90 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/rectovaginal-fistula-market-7138


About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:

Oncology Information Systems Market to Observe Significant Growth by 2018

Market Scenario
Global oncology information systems (OIS) market is expected to register a healthy CAGR over the forecast period. The market held a market value of USD 2,356.6 million in 2017 and is projected to grow at a CAGR of 7.5% during the forecast period. OIS is a comprehensive information and image management solution that facilitates the management of patient treatment schedules, treatment plans, treatment delivery, and treatment summaries. This system involves the exchange of information between radiation therapy departments and the healthcare enterprises. Factors attributed for the market growth are worldwide growing geriatric population along with rising prevalence of cancer, increasing investments in cancer research, and technological advancements in OIS. The International Agency for Research on Cancer (IARC) stated that there were 14 million new cases of cancer in 2012, that grew to 17.0 million in 2018, which is anticipated to reach to more than 22 million by 2030. Progress in developing treatments is enabling investors to invest in oncology research. Increasing equity investments in cancer-therapeutics startups is foreseen to shape the OIS vertical in the near future. On the contrary, higher costs associated with OIS services are anticipated to restrain the market growth over the forecast period.
Key players
Accuray Incorporated, Cerner Corporation, Philips Healthcare, McKesson Corporation, Altos Solutions, Inc., Elekta AB, Varian Medical Systems, Inc., Flatiron Health, Inc., RaySearch Laboratories, Epic Systems Corporation, Bogardus Medical Systems, Inc., and CureMD Healthcare are some of the prominent players in the global oncology information systems market.
Segmentation
The global oncology information systems market has been segmented into product & service type, application, and end user.
By product & service type, the market has been segmented into software and professional services. The software segment is further categorized into patient information systems and treatment planning systems. The professional services segment is further divided into consulting/optimization services, implementation services, and post-sale & maintenance services. The software for patient information systems segment spearheaded the market in 2017 as these systems offer advantages including planned treatment and remote access due to digital availability as compared to conventional record maintenance methods.
On the basis of application, the market has been classified into medical oncology, radiation oncology, and surgical oncology. The medical oncology segment would lead the market over the forecast period owing to rising applications of OIS in efficiently managing, interpreting, analyzing, and storing the patient information, as well as, in predicting the treatment results for patients, thereby improving their survival rates.
Based on end user, the market has been categorized into hospitals & oncology clinics, government institutes, and research centers.
The global oncology information systems market has been segmented by region into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The oncology information systems market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The European oncology information systems market has been segmented into Western Europe and Eastern Europe. The Western Europe oncology information systems market has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.
The oncology information systems market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The oncology information systems market in the Middle East & Africa has been segmented into the Middle East and Africa.
Regional Market Summary
Geographically, the Americas would grab the highest market share over the forecast period due to the presence of oncology information systems providers, changing lifestyle coupled with rising burden of cancer, increasing expenditure on healthcare, and adoption of oncology information systems in the US and Canada. The IARC reported that in 2018, the Americas have 13.3% of the global population and accounted for 21.0% of incidence and 14.4% of mortality worldwide.
The oncology information systems market in the Middle East & Africa will exhibit considerable market growth rate from 2018 to 2023. Majority of the regional market is likely to govern by the Middle East region due to the presence of world-class cancer treatment centers in Dubai, Saudi Arabia, increasing healthcare sector reforms, and gradually rising investments in OIS sector.
Growing adoption of OIS in European countries, namely, UK, Germany, France, Italy, and Spain, as the major market value contributors such as Philips Healthcare, Elekta AB, and RaySearch Laboratories are headquartered in the region.
Asia-Pacific would represent the phenomenal growth during the forecast period due to growing elderly population coupled with rising prevalence of cancer. The World Health Organization (WHO) and IARC reported that the proportions of cancer deaths in Asia (57.3%) are higher than the proportions of incident cases (48.4%) due to the higher frequency of certain cancer types associated with poorer prognosis and higher mortality rates.
Browse Complete 90  Pages Premium Research Report Enabled with 81 Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/oncology-information-systems-market-7080


About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:

Latest Study Offers Detailed Insights on Acromegaly Market 2018

Market Scenario
Acromegaly is a chronic metabolic disorder caused by excess secretion of growth hormone (GH) by the pituitary gland.  The excess secretion of GH results in gradual enlargement of body tissues including the bones of the face, jaw, hands, feet, and skull. Acromegaly is a rare disease, which is the most often diagnosed in the middle-aged adults and affects 5-8 people per 1 lakh people. If the diseases remains untreated, it may cause serious illness and premature death. The market is experiencing rapid growth owing to increasing prevalence of acromegaly, changing lifestyle and increasing need for better treatment & cost-effective treatment. Additionally, increasing government support along with the per capita income fuels the market growth. However, the cost of the treatment ranges from USD 2,800 to USD 9,200. On the other hand, the market may witness slow growth over the assessment period due to high cost of treatment and limited number of treatment.
The Global Acromegaly Market is expected to grow at a CAGR of ~5.2 % during the forecast period 2017-2023.
Regional Analysis
Asia Pacific is the fastest growing acromegaly market. China, and India are the significant contributors to the market growth due to the presence of huge population base, increasing prevalence of acromegaly, rapidly growing healthcare sector, and increasing healthcare expenditure. Whereas, the Middle East & Africa holds the least share of the global market due to poor economic condition and limited availability of medical facilities in African region. The Middle East & African acromegaly market is majorly driven by the UAE, Saudi Arabia, and Kuwait.
The Americas commands the global market owing to increasing prevalence of acromegaly, large patient population, high healthcare spending, and strong government support for research & development. According to the Health Research Funding Organization, in America, over 3,000 new cases of acromegaly occurs per year.
Europe leads the second position of the global the market, which is followed by Asia Pacific. High healthcare expenditure, well developed healthcare sector, and increasing government support drives the growth of the market.
Key Players
Some of key the players in the market are Novartis AG (Switzerland), Aegis Therapeutics LLC (US), Chiasma Inc (US), Crinetics Pharmaceuticals Inc (US), Daewoong Pharmaceutical Co Ltd (South Korea), Peptron Inc (South Korea), Silence Therapeutics Plc (UK), Strongbridge Biopharma plc (US), Amryt Pharma plc (UK), Foresee Pharmaceuticals LLC (US), Glide Pharmaceutical Technologies Ltd (US), Ionis Pharmaceuticals Inc (US), Ipsen SA (France)
Segmentation
Acromegaly market is segmented on the basis of type, diagnosis, treatment, and end user.
On the basis of treatment, the market is segmented into medications, surgery, radiation therapy, and others. The medication is further segmented into somatostatin analogues, dopamine agonists, growth hormone receptor antagonists, and others. The surgery is further segmented into endonasal transphenoidal surgery, and transphenoidal surgery.
On the basis of diagnosis, the market is segmented into medical imaging, medical laboratory investigations, others. The medical imaging is further segmented into radiography, magnetic resonance imaging (MRI), nuclear medicine, ultrasound, and others.
On the basis of type, the market is segmented into ectopic acromegaly, acromegaly due to growth hormone, and others.
Browse Complete 67 Pages Premium Research Report Enabled with Respective Tables and Figures at @ https://www.marketresearchfuture.com/reports/acromegaly-market-4429

         
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:

Keratoconus Treatment Market Research Report 2018 Analysis and Forecast to 2023

Market Scenario:
The Global Keratoconus Treatment Market has been evaluated as a rapidly growing market and it is expected to continue growing in the near future.
Approximately 3 million people are affected by this disease across the globe. Advanced diagnostic and treatment options are key drivers for this market. Increasing awareness of the disease, increasing funding for R&D and growing demand from emerging regions such as Asia are major driving forces of the market. Major players of this market are investing in R&D to develop effective solution for keratoconus. Introduction of wide range of lenses is important factor for market growth.
The market for keratoconus treatment was around USD 322.7 million in 2016 and is expected to reach USD 427.5 million by 2023 which is a projected CAGR of 4.1%.
Keratoconus KC is a condition of the eye which results in liberal thinning of the cornea. This may result in blurry vision, double vision, near sightedness, astigmatism, and light sensitivity. Usually both eyes are affected. In more severe cases a scarring or a circle may be seen within the cornea. While the cause is unknown, it is thought to occur due to a combination of genetic, environmental, and hormonal factors.
Further about seven percent of those affected have a family history of the condition, proposed environmental factors comprise of rubbing eyes and allergies. The fundamental mechanism involves changes of the cornea to a cone shape. Diagnosis is by examination with a slit lamp.
Moreover initially the condition can typically be corrected with glasses or soft contact lenses. As the disease worsens special contact lenses may be required. In most people the disease stabilizes after a few years without severe vision problems. In a small number of Keratoconus KC is a condition of the eye which results in liberal thinning of the cornea. This may result in blurry vision, double vision, near sightedness, astigmatism, and light sensitivity. Usually both eyes are affected. In more severe cases a scarring or a circle may be seen within the cornea. While the cause is unknown, it is thought to occur due to a combination of genetic, environmental, and hormonal factors.
Further about seven percent of those affected have a family history of the condition, proposed environmental factors comprise of rubbing eyes and allergies. The fundamental mechanism involves changes of the cornea to a cone shape. Diagnosis is by examination with a slit lamp.
The global keratoconus treatment market has been evaluated as a rapidly growing market and it is expected to continue growing in the near future.
Approximately 3 million people are affected by this disease across the globe. Advanced diagnostic and treatment options are key drivers for this market. Increasing awareness of the disease, increasing funding for R&D and growing demand from emerging regions such as Asia are major driving forces of the market. Major players of this market are investing in R&D to develop effective solution for keratoconus. Introduction of wide range of lenses is important factor for market growth. people scarring of the cornea occurs and a corneal transplantation is required
Key players for Global Keratoconus Treatment Market:                               
Some of the key players in this market are: Bausch & Lomb Incorporated (US), CIBA VISION (US), CooperVision (US), HOYA Vision Care (Singapore), Johnson & Johnson Vision Care, Inc. (US), Menicon Co., Ltd. (Japan), Novartis AG (Switzerland), Optik Seis (Indonesia), and SAFILENS S.R.L. (Italy), and others.
Segments:                                                                                                                                        
Global keratoconus treatment market has been segmented on the basis of type which comprises of forme fruste keratoconus, corneal hydrops, keratoglobus, pellucid marginal degeneration, posterior keratoconus, and others.
On the basis of end user, it is segmented into eye hospitals & clinics, medical research centers, academic institutes, and others.
On the basis of diagnosis, the market is segmented into computerized corneal mapping, keratometry, slit-lamp examination, refraction test, and others. Slit-lamp examination includes tonometry, vision testing, and others.
On the basis of treatments, the market has been segmented into lenses, surgery, collagen cross-linking, and others. Lenses is sub-segmented into eyeglasses or soft contact lenses, hard contact lenses, piggyback lenses, hybrid lenses, scleral lenses, and others. Surgery is sub-segmented into corneal inserts, cornea transplant, and others. Collagen cross-linking is still in research process and more study is required to implement this treatment option.
Regional
Considering the global scenario of the market, America is the highest revenue generator with North American region contributing the most. North America mainly includes US and Canada. US is one of the dominant markets not only in America but also in the global market. European market is the second largest and UK is believed to be the fastest growing market for keratoconus treatment in this region. Increasing awareness, growing purchasing power, and rapidly improving healthcare sector are driving the growth for Asia Pacific keratoconus market. Asia Pacific is one of the high potential market for keratoconus treatment. Due to slow adoption of new treatments and prosucts, Middle East and Africa is expected to grow at steady pace.
Browse Complete 80 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/keratoconus-treatment-market-3861

         
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:
Subscribe to: Posts (Atom)